We investigated the ability of isorhamnetin protect against hepatic fibrosis.
Isorhamnetin inhibited TGF-β1-induced fibrogenic gene expression in HSCs.
Isorhamnetin blocked TGF-β1-induced ROS production via Nrf2 activation.
Isorhamnetin significantly prevented CCl4-induced liver fibrosis in vivo.
Isorhamnetin may be a promising therapeutics for the liver fibrosis.